News and Trends 2 Jul 2025 Top biotech deals in June 2025 …system (CNS) therapeutics program. Sage’s postpartum depression drug will now be owned by Supernus. To add to that, American companies Carisma Therapeutics and OrthoCellix have merged. The new entity will… July 2, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 STORM Therapeutics closes $30M Series B financing …products targeting RNA modifying enzymes for oncology, inflammation, CNS, and viral diseases. I am delighted to welcome FTI and UTokyo IPC to the company and I would like to thank… December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Nov 2024 How biotech startups become unicorns …our lead candidate, APOC3, as well as candidates for the rest of our pipeline including our neuromuscular and central nervous system (CNS) programs,” said Martin. While scientific innovation and market… November 15, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Oct 2024 GPCR therapies: Eight promising biotechs hacking the cell signaling pathway …partnered with Japanese multinational Daiichi Sankyo to discover medicines for diseases that affect the central nervous system (CNS). More recently, it reeled in €60 million ($64.94 million) in a series… October 29, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 Oxford Firm Develops Better Test for ALS Diagnosis …that determine whether certain genes are active or inactive. At the World CNS Summit, Oxford BioDynamics presented data from two clinical trials gathering over 300 patients to study the ability… March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2025 First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? …system (CNS), characterized by behavioral issues such as hyperactivity and aggression, progressive cognitive decline leading to loss of speech and memory, sleep disorders, hearing loss, and difficulty walking. California-based Ultragenyx… September 29, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2023 Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma …nervous system (CNS) indications. “This acquisition underscores the Novartis commitment to bringing life-changing medicines forward for patients with neuromuscular diseases and other disorders of the nervous system,” said Robert Baloh,… July 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 15 Mar 2024 Reformulating psychedelics for neurodegenerative diseases …psychiatric diseases. Table of contents About Terran Biosciences The company has built a CNS-focused, tech-enabled drug development platform, and is advancing late-stage assets. These include a neuroimaging software platform (now… March 15, 2024 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2025 NLS Days: How do things look for biotech in Sweden? …(CNS) programs, with endocrinology/metabolism and infectious disease also prominent, a mix that’s now delivered more than 200 assets “available for partnering” in the newest edition of the Swedish Drug Discovery… October 17, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 31 Oct 2022 AI and biobanks could open the way to longevity treatments …rise with age and positively correlate with cognitive decline and all-cause mortality. We have created a series of novel central nervous system (CNS)-penetrant inhibitors of NLRP3 that we are developing… October 31, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2024 Five biotech companies taking Florida by storm …to directly target the root causes of diseases. Currently, its main focus is on developing therapies for central nervous system (CNS) and oncology indications. One of Myosin’s lead compounds, MT-125,… January 16, 2024 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 7 Nov 2025 Top biotech deals in October 2025 …the age of seven. The drug is made of sodium oxybate, a central nervous system (CNS) depressant, and its revenues are poised to hit $275 million by the end of this… November 7, 2025 - 13 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email